EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Efficacy, Mechanisms, and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients

Vikas S Sridhar iD, Luxcia Kugathasan iD, Yuliya Lytvyn iD, Hongyan Liu iD, Yangqing Deng iD, Leif Erik Lovblom iD, Massimo Nardone iD, Darren A Yuen iD, Yixiao Chen iD, Jonathan Hua, Yarden Aronson, Mai Mohsen iD und 8 weitere

Clinical Journal of the American Society of Nephrology · 2026-04 · 21 (4) · 664-679

DOI: 10.2215/cjn.0000000951 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 12.12.2025. Verfasst von Vikas S Sridhar und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Glucosides, Benzhydryl Compounds, Kidney Transplantation. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Heart and Stroke Foundation of Canada, University Health Network Foundation, Ajmera Transplant Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points The effIcacy, mechaNisms and saFety of SGLT2 INhibitors in kIdney Transplant recIpients trial assessed the physiologic effects of sodium-glucose cotransporter-2 inhibitors in kidney transplant recipients. In kidney transplant recipients, sodium-glucose cotransporter-2 inhibitors lowered mean arterial pressure after 1 week, reduced GFR, increased glucosuria, and were safe. Dapagliflozin was well tolerated in kidney transplant recipients, showing similar cardio-kidney effects seen in other groups; outcome trials in kidney transplant recipients are now needed.

Background

Cardiovascular and kidney protective mechanisms with 12 weeks of sodium-glucose cotransporter-2 inhibitor treatment (dapagliflozin 10 mg daily) were assessed in kidney transplant recipients (KTR) with and without type 2 diabetes.

Methods

This randomized double-blind, parallel-group, placebo-controlled study enrolled 52 KTR and comprised three sequential physiologic assessments under clamped euglycemia (4–6 mmol/L): baseline, at 1, and 12 weeks of treatment. The primary objective was to evaluate BP lowering with dapagliflozin. Secondary outcomes were iohexol-measured GFR, natriuresis, body composition, noninvasive cardiac output monitoring, arterial stiffness, heart rate variability, neurohormones, and safety.

Results

Fifty-one KTR completed the study—mean age 53±13 years, 62% with hypertension, 57% with type 2 diabetes, 50% on renin-angiotensin-aldosterone system inhibitors, and mean eGFR 68.2±24.4 ml/min per 1.73 m 2 . Compared with placebo, dapagliflozin did not lower systolic BP at 1 or 12 weeks, although it did reduce mean arterial pressure after 1 week (3.9 mm Hg; 95% confidence interval [CI], −7.5 to −0.2). Dapagliflozin led to significant, placebo-adjusted reductions in iohexol-measured GFR from baseline to 1 week (4.2 ml/min per 1.73 m 2 ; 95% CI, −7.14 to −1.24 ml/min per 1.73 m 2 ) and 12 weeks (−3.49 ml/min per 1.73 m 2 ; 95% CI, −6.33 to −0.64). Dapagliflozin significantly increased glucosuria without altering proximal sodium handling or evidence of sympathetic activation. Acute decreases in arterial stiffness (carotid augmentation index, −3.5%; 95% CI, −6.0 to −1.1) were observed in the dapagliflozin group after 12 weeks, although this was not significant compared with placebo. Dapagliflozin was generally safe and well tolerated. No episodes of urinary tract or genitourinary infections were observed in either treatment group throughout the trial.

Conclusions

Dapagliflozin activated expected physiologic pathways, although key differences observed in KTR might suggest mechanistic heterogeneity compared with nontransplant populations. Clinical trials evaluating sodium-glucose cotransporter-2 inhibitors in KTR are important to determine whether these mechanistic effects translate to improvements in kidney and cardiovascular outcomes. Clinical Trial registry name and registration number: ClinicalTrials.gov, NCT04965935. Podcast This article contains a podcast at https://dts.podtrac.com/redirect.mp3//www.asn-online.org/media/podcast/JASN/2026_02_09_KTS_February2026.mp3

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsGlucosidesBenzhydryl CompoundsKidney TransplantationDiabetes Mellitus, Type 2HumansDouble-Blind MethodMiddle AgedMaleFemaleGlomerular Filtration RateAdultAgedTreatment OutcomeArterial Pressure

Stichwörter der Autor:innen

GFRSGLT2 inhibitorscardiovascular-kidney-metabolic (CKM) syndromediabetes mellitusimmunosuppressionkidney transplantationrandomized controlled trialsrenal functionsystolic BP

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGlucosidesBenzhydryl Compoundsdapagliflozin

Autor:innen und Institutionen

  • Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Division of Nephrology, Department of Medicine, University Health Network, Toronto, Ontario, Canada.
  • Biostatistics Department, University Health Network, Toronto, Ontario, Canada.
  • Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
  • Division of Nephrology, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Vikas S Sridhar, Luxcia Kugathasan, Yuliya Lytvyn, Hongyan Liu, Yangqing Deng, Leif Erik Lovblom, Massimo Nardone, Darren A Yuen, Yixiao Chen, Mai Mohsen, Jacob A Udell, Bruce A Perkins, Jasper Stevens, Daan J Touw, Hiddo J L Heerspink, David Z I Cherney, Sunita K S Singh

Förderung

  • Heart and Stroke Foundation of Canada
  • University Health Network Foundation
  • Ajmera Transplant Center

Zitieren

APA

Sridhar, V. S., Kugathasan, L., Lytvyn, Y., Liu, H., Deng, Y., Lovblom, L. E., Nardone, M., Yuen, D. A., Chen, Y., Hua, J., Aronson, Y., Mohsen, M., Kim, S. J., Udell, J. A., Perkins, B. A., Stevens, J., Touw, D. J., Heerspink, H. J. L., Cherney, D. Z. I., & Singh, S. K. S. (2026). Efficacy, Mechanisms, and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology, 21(4), 664-679. https://doi.org/10.2215/cjn.0000000951

Vancouver

Sridhar VS, Kugathasan L, Lytvyn Y, Liu H, Deng Y, Lovblom LE, et al. Efficacy, Mechanisms, and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology. 2026;21(4):664-679. doi:10.2215/cjn.0000000951

BibTeX
@article{Sridhar2026,
  author = {Sridhar, Vikas S and Kugathasan, Luxcia and Lytvyn, Yuliya and Liu, Hongyan and Deng, Yangqing and Lovblom, Leif Erik and Nardone, Massimo and Yuen, Darren A and Chen, Yixiao and Hua, Jonathan and Aronson, Yarden and Mohsen, Mai and Kim, S Joseph and Udell, Jacob A and Perkins, Bruce A and Stevens, Jasper and Touw, Daan J and Heerspink, Hiddo J L and Cherney, David Z I and Singh, Sunita K S},
  title = {Efficacy, Mechanisms, and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients},
  journal = {Clinical Journal of the American Society of Nephrology},
  year = {2026},
  volume = {21},
  number = {4},
  pages = {664--679},
  doi = {10.2215/cjn.0000000951}
}
Kostenlos starten →